eligibility_summary
Adults (≥18) with measurable PD-L1+ (CPS ≥1) R/M HNSCC (not salivary, EBV+ NPX, skin), ECOG 0–1, progressed after ≥6 wks 1L ICI, no prior anti‑angiogenic therapy. Exclude unresolved ≥G3 irAEs, ICI hyperprogression, bleeding risk/therapeutic anticoagulation, uncontrolled HTN/coagulopathy, active infection, pneumonitis, prior transplant, active autoimmune disease, pregnancy. Controlled HIV/HBV/HCV and treated brain mets allowed, labs OK, no recent major surgery or uncontrolled effusions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II/III randomized trial in recurrent/metastatic HNSCC after prior immune checkpoint inhibitor. Arms: (A) chemotherapy [cisplatin or carboplatin (platinum DNA crosslinkers) + docetaxel (taxane microtubule stabilizer)] + cetuximab (chimeric anti‑EGFR monoclonal antibody), (B) same chemotherapy + bevacizumab (humanized anti‑VEGF‑A monoclonal antibody, antiangiogenic), (C) bevacizumab + atezolizumab (humanized anti‑PD‑L1 monoclonal antibody, checkpoint inhibitor). Targets/pathways: PD‑1/PD‑L1 axis to reinvigorate cytotoxic T cells, VEGF/VEGFR signaling on endothelial cells to block tumor angiogenesis and normalize vasculature, EGFR on tumor cells to inhibit growth and enable ADCC, DNA damage/replication stress via platinum adducts, mitotic spindle/microtubules via docetaxel.